Sun Pharma Advanced Research Co. Ltd. (IN:SPARC)
:SPARC
SPARC Stock Chart & Stats
₹135.70
-₹2.58(-1.32%)
At close: 4:00 PM EST
₹135.70
-₹2.58(-1.32%)
Day’s Range― - ―
52-Week Range₹108.20 - ₹204.25
Previous CloseN/A
Volume383.41K
Average Volume (3M)24.00K
Market Cap
₹40.37B
Enterprise Value₹44.42B
Total Cash (Recent Filing)₹30.00M
Total Debt (Recent Filing)₹4.17B
Price to Earnings (P/E)―
Beta1.58
Next Earnings
May 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.48
Shares Outstanding324,521,580
10 Day Avg. Volume27,089
30 Day Avg. Volume24,005
Financial Highlights & Ratios
PEG Ratio1.20
Price to Book (P/B)-21.89
Price to Sales (P/S)66.17
P/FCF Ratio-12.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Licensing / Partnership Monetization ModelSPARC’s primary monetization via out-licensing, milestones and royalties creates a capital-efficient pathway to convert R&D into cash. Durable partner-funded development and milestone payouts can de-risk spend, provide non-linear upside and preserve equity capital as programs mature.
Focus On Novel & Specialty Therapeutics R&DA sustained focus on novel and specialty therapeutics and NCEs supports differentiated asset creation. This builds long-term technical barriers, enhances attractiveness to large pharma partners for licensing, and underpins potential high-value deals that can fund future development.
Improvements In Cash ManagementNoted improvements in cash management, if maintained, can extend runway and reduce near-term financing needs. Structural tightening of cash conversion and discipline lowers dilution risk and provides management more time to reach milestones or secure partner funding.
Bears Say
Negative Stockholders' Equity & High LeverageNegative equity and elevated leverage are persistent structural liabilities that constrain financial flexibility. They increase refinancing and covenant risk, can elevate funding costs, and may deter counterparties or limit the company’s ability to pursue opportunistic deals or strategic investments.
Persistent Negative Operating & Free Cash FlowContinued operating cash burn necessitates repeated external financing, raising dilution and liquidity risk. Over months this constrains R&D prioritization, limits ability to self-fund program advancement, and increases dependency on milestone-driven partner payments to sustain operations.
Sustained Profitability Weakness & Revenue DeclinesOngoing losses and inconsistent, declining revenue indicate the business hasn’t achieved stable commercial traction. This undermines internal reinvestment capacity, increases pressure for external funding, and reduces negotiating leverage with potential partners over the medium term.
Sun Pharma Advanced Research Co. Ltd. News
SPARC FAQ
What was Sun Pharma Advanced Research Co. Ltd.’s price range in the past 12 months?
Sun Pharma Advanced Research Co. Ltd. lowest stock price was ₹108.20 and its highest was ₹204.25 in the past 12 months.
What is Sun Pharma Advanced Research Co. Ltd.’s market cap?
Sun Pharma Advanced Research Co. Ltd.’s market cap is ₹40.37B.
When is Sun Pharma Advanced Research Co. Ltd.’s upcoming earnings report date?
Sun Pharma Advanced Research Co. Ltd.’s upcoming earnings report date is May 25, 2026 which is in 49 days.
How were Sun Pharma Advanced Research Co. Ltd.’s earnings last quarter?
Sun Pharma Advanced Research Co. Ltd. released its earnings results on Feb 09, 2026. The company reported -₹2.478 earnings per share for the quarter, missing the consensus estimate of N/A by -₹2.478.
Is Sun Pharma Advanced Research Co. Ltd. overvalued?
According to Wall Street analysts Sun Pharma Advanced Research Co. Ltd.’s price is currently Overvalued.
Does Sun Pharma Advanced Research Co. Ltd. pay dividends?
Sun Pharma Advanced Research Co. Ltd. does not currently pay dividends.
What is Sun Pharma Advanced Research Co. Ltd.’s EPS estimate?
Sun Pharma Advanced Research Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sun Pharma Advanced Research Co. Ltd. have?
Sun Pharma Advanced Research Co. Ltd. has 324,521,580 shares outstanding.
What happened to Sun Pharma Advanced Research Co. Ltd.’s price movement after its last earnings report?
Sun Pharma Advanced Research Co. Ltd. reported an EPS of -₹2.478 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.755%.
Which hedge fund is a major shareholder of Sun Pharma Advanced Research Co. Ltd.?
Currently, no hedge funds are holding shares in IN:SPARC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sun Pharma Advanced Research Co. Ltd.
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited
Technical Analysis
Aarti Drugs Limited
―
RPG Life Sciences Limited
―
Supriya Lifescience Limited
―
Suven Life Sciences Limited
―
Thyrocare Technologies Ltd
―